Search

Displaying results 4501 - 4510 of 7283 in total
  1. Drug

    Givinostat

    go.drugbank.com/drugs/DB12645
    ApprovedInvestigational

    Givinostat is a small molecule histone deacetylase (HDAC) inhibitor. … It has been investigated as a treatment for a variety of inflammatory diseases, like Crohn's disease and juvenile idiopathic arthritis, cancers like leukemia and lymphoma, as well as several muscular dystrophies

  2. Drug

    Acoramidis

    go.drugbank.com/drugs/DB17999
    ApprovedInvestigational

    [A264768] Although they share a mechanism of action, acoramidis is more selective for TTR and is a more potent stabilizer when compared to tafamidis. … Acoramidis is a small molecule stabilizer of transthyretin (TTR) for use in patients with TTR amyloidosis.

  3. Drug

    Enzalutamide

    go.drugbank.com/drugs/DB08899
    ApprovedInvestigational

    [A252667] Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide. … Compared to the average time of 10 to 15 years for a drug to go from pre-clinical to clinical studies, enzalutamide was developed relatively rapidly.[A252667]

    Products: Enzalutamid 1A Pharma 40 mg - Filmtabletten, Enzalutamid 1A Pharma 80 mg - Filmtabletten
  4. Drug

    Melaleuca alternifolia leaf

    go.drugbank.com/drugs/DB14372
    Investigational

    Melaleuca alternifolia leaf is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

    Mixtures: Dr. SEED Teatree and Lime Vegan No-sebum Cool Anti HairlossShampoo
  5. Drug

    Febuxostat

    go.drugbank.com/drugs/DB04854
    ApprovedInvestigational

    [A39743] In early 2008, febuxostat was granted marketing authorization by the European Commission for the treatment of chronic hyperuricemia and gout. … Febuxostat is a non-purine xanthine oxidase (XO) inhibitor.

    Products: FEBUXOSTAT 1A PHARMA 80MG, FEBUXOSTAT 1A PHARMA 120MG
  6. Drug

    Trofinetide

    go.drugbank.com/drugs/DB06045
    Approved

    Trofinetide is a novel synthetic analog of [glypromate], also known as glycine–proline–glutamate (GPE), a naturally occurring protein in the brain and the N-terminal tripeptide of insulin-like growth factor … [A258438] Trofinetide was approved by the FDA on March 10, 2023, for the treatment of Rett syndrome,[L45718,L45748] which is an X-linked neurodevelopmental disorder characterized by a range of cognitive

  7. Drug

    5-methyltetrahydrofolic acid

    go.drugbank.com/drugs/DB04789
    InvestigationalNutraceutical

    5-methyltetrahydrofolic acid is a methylated derivate of tetrahydrofolate.

    International brands: Prefolic AMixtures: FeRiva 21-7 28-Day
  8. Drug

    Relugolix

    go.drugbank.com/drugs/DB11853
    ApprovedInvestigational

    [L27991,L27996] This branded product was later approved by the European Commission on April 29, 2022.[L42150] Relugolix has also been studied in the symptomatic treatment of endometriosis. … Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions.

  9. Drug

    Sotagliflozin

    go.drugbank.com/drugs/DB12713
    ApprovedInvestigational

    [L39734] A similar approval has also been sought in the US, but the FDA has since published a proposal to refuse the approval because the data submitted did not show that it was safe under the proposed … 1 diabetes mellitus (T1DM) and a BMI ≥27 kg/m<sup>2</sup>.

  10. Drug

    BHT-3034

    go.drugbank.com/drugs/DB18045
    Experimental

    BHT-3034 is a DNA plasmid vaccine immunotherapy under investigation for the treatment of myasthenia gravis.[L48086]